BMRN vs ALNY Stock Comparison: AI Score, Valuation, Performance and Upside
BioMarin and Alnylam are both rare disease biopharmaceutical companies with distinct therapeutic modalities and commercial drug portfolios. BioMarin specializes in enzyme replacement therapies for metabolic genetic disorders; Alnylam uses RNA interference to silence disease-causing genes. Both are investing in gene therapy and platform expansion, though at different stages of commercial scale and profitability.
BMRN vs ALNY compares a rare disease ERT incumbent with gene therapy ambitions (BioMarin) against the RNAi platform pioneer building toward profitability on a novel drug modality (Alnylam) — BioMarin offers more current profitability, while Alnylam offers more platform technology upside if RNAi extends into large common disease markets.
BMRN holds the edge across 3 of 5 key metrics in this comparison. BMRN leads on both 1-year return (+15.96%) and forward P/E quality (10.20x vs 19.94x for ALNY), a relatively favorable combination of momentum and valuation. On fundamentals, ALNY is growing revenue faster (66.90%), while BMRN maintains the higher operating margin (21.16%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for ALNY (+49.33%) than for BMRN (+36.51%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- prefer a profitable rare disease company with multiple commercial ERT products and deep lysosomal storage disorder expertise
- value Voxzogo achondroplasia as a growing pediatric rare disease franchise independent of legacy ERT revenues
- want more immediate profitability from rare disease investing vs Alnylam's earlier profitability timeline
- are comfortable with Roctavian gene therapy commercial challenges and limited organic ERT growth requiring pipeline reinvestment
- prefer the RNAi pioneer platform with potential to address genetic and common diseases through gene silencing
- value Amvuttra's growing hATTR franchise and Leqvio cardiovascular partnership as two distinct commercial vectors
- want platform technology upside if RNAi programs in hypertension and complement achieve late-stage clinical success
- are comfortable with delayed GAAP profitability as Alnylam invests in pipeline and Amvuttra commercial scale
| Metric | BMRN | ALNY |
|---|---|---|
| AI scorei | 27.5 | 53.1 |
| AI ranki | #2432 | #356 |
| Latest closei | $63.94 | $239.56 |
| 1M returni | -7.77% | -1.26% |
| 6M returni | +16.19% | -23.00% |
| 1Y returni | +15.96% | -47.02% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BMRN | ALNY |
|---|---|---|
| 1Y ago | $11.6K (+16.0%) started 2025-09-18 | $5.3K (-47.0%) started 2025-09-18 |
| 5Y ago | $8.26K (-17.4%) started 2021-09-20 | $13.06K (+30.6%) started 2021-09-20 |
| 10Y ago | $6.52K (-34.8%) started 2016-09-19 | $31.07K (+210.7%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | BMRN | ALNY |
|---|---|---|
| Market capi | $12.91B | $33.28B |
| Trailing P/Ei | 180.24 | 43.32 |
| Forward P/Ei | 10.20 | 19.94 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 4.66 | 6.86 |
| Analyst targeti | $91.04 | $371.35 |
| Target upsidei | +36.51% | +49.33% |
| Metric | BMRN | ALNY |
|---|---|---|
| Revenue growthi | 19.90% | 66.90% |
| Earnings growthi | -81.30% | N/A |
| EPS growthi | -81.30% | N/A |
| FCF margini | +2.50% | +5.65% |
| Operating margini | 21.16% | 17.93% |
| Profit margini | 2.14% | 16.13% |
| ROIC proxyi | 1.18% | 96.56% |
| Return on equityi | 1.18% | 96.56% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.23 | 0.30 |
| Debt/equityi | 66.47 | 220.62 |
| Current ratioi | 2.39 | 3.06 |
| Quick ratioi | 1.16 | 2.79 |
Over the past year, BMRN and ALNY have moved weakly in the same direction (correlation of 0.22), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BMRN | ALNY |
|---|---|---|---|
| 1Y | Growthi | +15.96% | -47.02% |
| CAGRi | +15.97% | -47.04% | |
| Volatilityi | 35.04% | 47.10% | |
| Sharpe ratioi | 0.47 | -1.19 | |
| Sortino ratioi | 0.84 | -1.41 | |
| Max drawdowni | 22.49% | 58.17% | |
| Current drawdowni | 8.97% | 51.23% | |
| Avg drawdowni | 7.56% | 29.90% | |
| Ulcer Indexi | 9.16% | 34.03% | |
| Max daily dropi | 4.35% | 28.31% | |
| Max wkly dropi | 8.75% | 24.38% | |
| 5Y | Growthi | -17.37% | +30.58% |
| CAGRi | -3.75% | +5.49% | |
| Volatilityi | 32.91% | 50.93% | |
| Sharpe ratioi | -0.09 | 0.26 | |
| Sortino ratioi | -0.13 | 0.41 | |
| Max drawdowni | 57.64% | 58.17% | |
| Current drawdowni | 45.48% | 51.23% | |
| Avg drawdowni | 29.19% | 20.20% | |
| Ulcer Indexi | 34.23% | 24.45% | |
| Max daily dropi | 17.71% | 28.31% | |
| Max wkly dropi | 17.74% | 24.38% | |
| 10Y | Growthi | -34.83% | +210.71% |
| CAGRi | -4.19% | +12.01% | |
| Volatilityi | 35.04% | 54.27% | |
| Sharpe ratioi | -0.07 | 0.40 | |
| Sortino ratioi | -0.10 | 0.61 | |
| Max drawdowni | 62.09% | 59.78% | |
| Current drawdowni | 51.20% | 51.23% | |
| Avg drawdowni | 30.07% | 22.91% | |
| Ulcer Indexi | 34.38% | 27.78% | |
| Max daily dropi | 35.28% | 48.49% | |
| Max wkly dropi | 38.91% | 49.44% |
| Category | BMRN | ALNY |
|---|---|---|
| Company | BioMarin Pharmaceutical Inc. | Alnylam Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | BioMarin is a rare disease biopharmaceutical company specializing in enzyme replacement therapy (ERT) and gene therapy for genetic disorders. Its commercial portfolio includes Vimizim (MPS IVA), Naglazyme (MPS VI), Aldurazyme (MPS I, co-marketed with Genzyme), Brineura (CLN2), and Palynziq (PKU). Roctavian (gene therapy for hemophilia A) was approved but has faced commercial challenges. BioMarin has deep rare disease expertise across lysosomal storage disorders and metabolic diseases. | Alnylam is the pioneer of RNA interference (RNAi) therapeutics, with a commercial portfolio including Amvuttra (vutrisiran for hATTR), Onpattro (patisiran), Givlaari (givosiran for AHP), and Oxlumo (lumasiran for PH1). Leqvio (inclisiran for high cholesterol), licensed to Novartis, adds a large cardiovascular revenue stream. Alnylam's RNAi platform enables silencing of virtually any expressed gene, providing a broad modality applicable to genetic and common diseases alike. |
| Investor focus | Investors track enzyme replacement therapy revenue growth and durability, Roctavian hemophilia A gene therapy uptake, Voxzogo (achondroplasia) pediatric growth disorder revenue ramp, and overall revenue diversification beyond legacy ERT products. | Investors focus on Amvuttra quarterly revenue growth, Leqvio patient adoption milestones, pipeline programs in hypertension and complement disorders, and timeline to sustained GAAP profitability. |
- Deep expertise in lysosomal storage disorders with multiple commercially approved ERTs and a dominant rare disease manufacturing capability
- Voxzogo (vosoritide) for achondroplasia is a growing pediatric rare bone disorder franchise with global rollout potential
- Long track record of navigating rare disease regulatory pathways and patient advocacy relationships enabling efficient launches
- RNAi platform is a scientifically distinct drug modality with the ability to silence genes that small molecules or antibodies cannot target
- Amvuttra's quarterly subcutaneous dosing is a significant convenience advantage over Onpattro's biweekly IV infusion for hATTR patients
- Leqvio partnership with Novartis for lipid lowering expands Alnylam's commercial reach into mass-market cardiovascular without full commercial investment
- Roctavian hemophilia A gene therapy has faced adoption challenges — reimbursement hurdles and competition from factor prophylaxis have limited uptake
- ERT market maturity means existing products have limited organic growth — new product launches are essential for revenue re-acceleration
- BioMarin's pipeline requires significant R&D investment to maintain the company's rare disease relevance beyond current product life cycles
- Path to GAAP profitability requires Amvuttra reaching significant scale — currently still operating at a loss
- hATTR market competition from Pfizer's Vyndamax/Vyndaqel (tafamidis stabilizers) and BridgeBio's acoramidis creates a competitive market
- Pipeline programs in hypertension and complement are high value but years from potential approval
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.